Orexo AB
STO:ORX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Orexo AB
Other Current Liabilities
Orexo AB
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Orexo AB
STO:ORX
|
Other Current Liabilities
kr163m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
2%
|
|
|
Camurus AB
STO:CAMX
|
Other Current Liabilities
kr50.9m
|
CAGR 3-Years
14%
|
CAGR 5-Years
29%
|
CAGR 10-Years
-6%
|
|
|
E
|
Enzymatica AB (publ)
STO:ENZY
|
Other Current Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Swedencare AB (publ)
STO:SECARE
|
Other Current Liabilities
kr183.8m
|
CAGR 3-Years
6%
|
CAGR 5-Years
69%
|
CAGR 10-Years
58%
|
|
|
I
|
Infant Bacterial Therapeutics AB
STO:IBT B
|
Other Current Liabilities
kr387k
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
Other Current Liabilities
kr1.1m
|
CAGR 3-Years
119%
|
CAGR 5-Years
53%
|
CAGR 10-Years
N/A
|
|
Orexo AB
Glance View
Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. The company is headquartered in Uppsala, Uppsala and currently employs 121 full-time employees. The company went IPO on 2005-11-09. The company focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The firm has four commercialized products, several projects developed in partnership, as well as three development programs. The firm's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The firm operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
See Also
What is Orexo AB's Other Current Liabilities?
Other Current Liabilities
163m
SEK
Based on the financial report for Dec 31, 2025, Orexo AB's Other Current Liabilities amounts to 163m SEK.
What is Orexo AB's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
2%
Over the last year, the Other Current Liabilities growth was 34%. The average annual Other Current Liabilities growth rates for Orexo AB have been 4% over the past three years , -4% over the past five years , and 2% over the past ten years .
